Creo Medical Group PLC Result of AGM (4900Q)

TIDMCREO

RNS Number : 4900Q

Creo Medical Group PLC

28 June 2022

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Result of AGM

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that all resolutions put to shareholders at the Company's Annual General Meeting held earlier today were duly passed.

The voting results will be made available on the Investor Relations section of the Company's website shortly: https://creomedical.com/investors/reports-and-presentations/

Enquiries:

 
 Creo Medical Group plc                                                  www.creomedical.com 
 Richard Rees (CFO)                                                      [phone] 
 
 Cenkos Securities plc                                                   [phone] 
 Stephen Keys / Camilla Hume (NOMAD) 
 Michael Johnson / Russell Kerr (Sales) 
 
 Numis Securities Limited (Joint 
  Broker) 
  Freddie Barnfield / James Black 
  / Duncan Monteith                                                      [phone] 
 
 Walbrook PR Ltd                           Tel: + 44 ( 0)20 7933 8780 or [e-mail] 
 Paul McManus / Sam Allen /                           Mob: [phone] 
  Phillip Marriage                                             558 258 / [phone] 
 

About Creo Medical

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUWOARUUUNUAR

(END) Dow Jones Newswires

June 28, 2022 07:33 ET (11:33 GMT)